TriVentures

BioProtect Ltd. is an international medical device startup focused on developing and commercializing biodegradable balloon spacers designed to protect normal tissue during cancer radiation therapy. The company's flagship product, the ProSpace balloon spacer, has demonstrated superior efficacy and safety in safeguarding the rectum during radiation treatment for prostate cancer. This innovative technology significantly reduces the risk of serious and chronic side effects associated with radiation, while enhancing tumor control. Founded in 2004 and headquartered in Israel, BioProtect also operates subsidiaries in Germany and the United States, aiming to address unmet clinical needs in the growing radiotherapy spacers market with its platform of biodegradable implantable balloons.

FeelBetter is a healthcare optimization platform founded in 2018 and based in Tel Aviv, Israel. The company focuses on value-based models to identify at-risk patients and recommend appropriate interventions. Its platform enhances both financial and clinical outcomes by analyzing individual health journeys, allowing healthcare organizations to diagnose potential issues before they escalate. By delivering personalized data and actionable insights, FeelBetter aims to improve the quality of care and overall business results for healthcare providers.

FEMSelect Inc. specializes in designing and developing surgical systems and devices for pelvic floor ligament fixation, focusing on women's health. The company is known for its innovative EnPlace system, a minimally invasive and mesh-free solution for treating pelvic organ prolapse (POP). This patented technology allows for precise guidance and deployment of an anchor unit that stabilizes the pelvic floor ligament through a vaginal approach, significantly enhancing patient recovery and comfort. The procedure typically takes about 30 minutes and does not require overnight hospital stays or result in visible scarring. Founded in 2012, FEMSelect operates from its headquarters in Newark, Delaware.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

EyeYon Medical Ltd. is an Israeli company specializing in the development of medical devices for the treatment of corneal edema. Founded by a team of experienced professionals in ophthalmology and business, the company is based in Jerusalem and operates within the Van Leer Technology Incubator. Its key products include Hyper-CL, a hyperosmotic contact lens that utilizes osmosis to extract fluids from corneal edema, thereby improving vision and alleviating pain. Additionally, EyeYon Medical offers DSPEK, an artificial endothelial layer designed to replace damaged endothelial tissue, which is crucial in cases of corneal edema. The company's innovative solutions are non-invasive, comfortable, and facilitate effective eye care for patients dealing with both acute and chronic ocular conditions.

Genoox, Ltd. is a company that develops a cloud-based platform for managing and analyzing genomic data. Founded in 2014, the company aims to create a comprehensive network of real-world genomic and clinical data to enhance genetic diagnostics and personalized treatments. The platform connects clinicians, genetic counselors, and healthcare organizations, allowing them to share insights and make significant discoveries using advanced genomic tools and applications. By leveraging artificial intelligence and machine learning, Genoox's platform translates complex genetic data into actionable clinical information, helping healthcare providers to analyze rare genetic mutations and improve patient outcomes with increased accuracy and efficiency. The company is headquartered in Israel and serves over 1,700 health organizations across 44 markets worldwide.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

BioProtect Ltd. is an international medical device startup focused on developing and commercializing biodegradable balloon spacers designed to protect normal tissue during cancer radiation therapy. The company's flagship product, the ProSpace balloon spacer, has demonstrated superior efficacy and safety in safeguarding the rectum during radiation treatment for prostate cancer. This innovative technology significantly reduces the risk of serious and chronic side effects associated with radiation, while enhancing tumor control. Founded in 2004 and headquartered in Israel, BioProtect also operates subsidiaries in Germany and the United States, aiming to address unmet clinical needs in the growing radiotherapy spacers market with its platform of biodegradable implantable balloons.

Genoox, Ltd. is a company that develops a cloud-based platform for managing and analyzing genomic data. Founded in 2014, the company aims to create a comprehensive network of real-world genomic and clinical data to enhance genetic diagnostics and personalized treatments. The platform connects clinicians, genetic counselors, and healthcare organizations, allowing them to share insights and make significant discoveries using advanced genomic tools and applications. By leveraging artificial intelligence and machine learning, Genoox's platform translates complex genetic data into actionable clinical information, helping healthcare providers to analyze rare genetic mutations and improve patient outcomes with increased accuracy and efficiency. The company is headquartered in Israel and serves over 1,700 health organizations across 44 markets worldwide.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

CathWorks Ltd. is a medical technology company that specializes in enhancing percutaneous coronary intervention (PCI) therapy decisions through its advanced computational science platform. Founded in 2013 and headquartered in Kfar-Saba, Israel, with an additional office in the United States, the company has developed the CathWorks FFRangio, a non-invasive device that provides objective, multi-vessel physiologic measurements. This tool transforms coronary angiography from a subjective visual assessment into an objective decision-making framework based on fractional flow reserve (FFR) metrics. By utilizing sophisticated algorithms to process visual information, CathWorks aims to improve the efficiency of cath lab operations and support healthcare providers in making data-driven clinical decisions.

Colospan Ltd is a clinical-stage medical device company based in Kfar Saba, Israel, that specializes in developing innovative solutions for colorectal surgeries. Founded in 2010, the company has created proprietary technology aimed at preventing anastomotic leaks and minimizing the need for diverting colonic stomas. Its lead product is a single-use, temporary intraluminal bypass device designed to reduce contact between fecal matter and the anastomotic site after procedures such as colectomy, which is often necessary in cases of severe intestinal inflammatory diseases and bowel or rectal cancer. By addressing the risk of leakage that can lead to prolonged hospitalization or additional surgeries, Colospan's devices aim to improve patient outcomes and facilitate a smoother recovery process while mitigating post-operative complications.

Colospan Ltd is a clinical-stage medical device company based in Kfar Saba, Israel, that specializes in developing innovative solutions for colorectal surgeries. Founded in 2010, the company has created proprietary technology aimed at preventing anastomotic leaks and minimizing the need for diverting colonic stomas. Its lead product is a single-use, temporary intraluminal bypass device designed to reduce contact between fecal matter and the anastomotic site after procedures such as colectomy, which is often necessary in cases of severe intestinal inflammatory diseases and bowel or rectal cancer. By addressing the risk of leakage that can lead to prolonged hospitalization or additional surgeries, Colospan's devices aim to improve patient outcomes and facilitate a smoother recovery process while mitigating post-operative complications.

EyeYon Medical Ltd. is an Israeli company specializing in the development of medical devices for the treatment of corneal edema. Founded by a team of experienced professionals in ophthalmology and business, the company is based in Jerusalem and operates within the Van Leer Technology Incubator. Its key products include Hyper-CL, a hyperosmotic contact lens that utilizes osmosis to extract fluids from corneal edema, thereby improving vision and alleviating pain. Additionally, EyeYon Medical offers DSPEK, an artificial endothelial layer designed to replace damaged endothelial tissue, which is crucial in cases of corneal edema. The company's innovative solutions are non-invasive, comfortable, and facilitate effective eye care for patients dealing with both acute and chronic ocular conditions.

OrthoSpace Ltd. is an Israeli company specializing in the development and commercialization of biodegradable balloon systems designed to treat rotator cuff syndrome. Founded in 2009 and based in Caesarea, the company focuses on creating innovative solutions that aim to alleviate pain and enhance patients' range of motion while preserving their bone and joint structures. Its flagship product, InSpace™, has received the CE mark and is marketed in Europe, providing a non-invasive option for patients suffering from rotator cuff injuries. The balloon system mimics the function of the original bursa, acting as a spacer between the acromion and the humeral head to facilitate smooth movement and reduce friction during shoulder motion. As of 2019, OrthoSpace operates as a subsidiary of Stryker Corporation.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

OrthoSpace Ltd. is an Israeli company specializing in the development and commercialization of biodegradable balloon systems designed to treat rotator cuff syndrome. Founded in 2009 and based in Caesarea, the company focuses on creating innovative solutions that aim to alleviate pain and enhance patients' range of motion while preserving their bone and joint structures. Its flagship product, InSpace™, has received the CE mark and is marketed in Europe, providing a non-invasive option for patients suffering from rotator cuff injuries. The balloon system mimics the function of the original bursa, acting as a spacer between the acromion and the humeral head to facilitate smooth movement and reduce friction during shoulder motion. As of 2019, OrthoSpace operates as a subsidiary of Stryker Corporation.

EyeYon Medical Ltd. is an Israeli company specializing in the development of medical devices for the treatment of corneal edema. Founded by a team of experienced professionals in ophthalmology and business, the company is based in Jerusalem and operates within the Van Leer Technology Incubator. Its key products include Hyper-CL, a hyperosmotic contact lens that utilizes osmosis to extract fluids from corneal edema, thereby improving vision and alleviating pain. Additionally, EyeYon Medical offers DSPEK, an artificial endothelial layer designed to replace damaged endothelial tissue, which is crucial in cases of corneal edema. The company's innovative solutions are non-invasive, comfortable, and facilitate effective eye care for patients dealing with both acute and chronic ocular conditions.

FEMSelect Inc. specializes in designing and developing surgical systems and devices for pelvic floor ligament fixation, focusing on women's health. The company is known for its innovative EnPlace system, a minimally invasive and mesh-free solution for treating pelvic organ prolapse (POP). This patented technology allows for precise guidance and deployment of an anchor unit that stabilizes the pelvic floor ligament through a vaginal approach, significantly enhancing patient recovery and comfort. The procedure typically takes about 30 minutes and does not require overnight hospital stays or result in visible scarring. Founded in 2012, FEMSelect operates from its headquarters in Newark, Delaware.